June 1 (Reuters) - Pfizer Inc late on Wednesday received the U.S. Food and Drug Administration's nod for its respiratory syncytial virus (RSV) vaccine for older adults, nearly a month after GSK's shot was approved by the regulator.

RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. The market for RSV vaccines could exceed $10 billion by 2030, according to analysts.

The following is a list of companies developing drugs and vaccines against the virus:

PFIZER

The FDA approved Pfizer's RSV shot, Abrysvo, for adults aged 60 and above to prevent lower respiratory tract disease.

Pfizer's vaccine was found to be nearly 67% effective among participants aged 60 and above with two or more symptoms in a late-stage study, and 85.7% against severe disease defined by three or more symptoms.

The shot had received U.S. FDA panel's backing last month for use in pregnant women to prevent the disease in infants.

GSK

U.S. health regulator approved GSK's RSV vaccine, Arexvy, in May, while Europe's health regulator recommended authorization for the shot in late April.

The company expects the vaccine to be available before the next RSV season in the United States.

GSK's vaccine was 82.6% effective against RSV infections in a late-stage study involving adults aged 60 and over, data showed in October last year.

MODERNA

Moderna's experimental messenger RNA vaccine for RSV was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.

The company plans to submit its application for U.S. approval of its vaccine, mRNA-1345, in the second quarter of 2023 for those aged 60 and older.

SANOFI AND ASTRAZENECA

In November last year, Sanofi and AstraZeneca gained the European Commission's marketing authorization for their antibody drug nirsevimab to prevent RSV-related disease in infants.

Nirsevimab in March last year showed an efficacy of 74.5% against some types of lower respiratory tract infections, compared with a placebo in infants in a late-stage study.

It is under review by the FDA.

MERCK

Merck & Co Inc is conducting a late-stage study of its experimental antibody drug clesrovimab to prevent RSV infections in infants and children, with the trial expected to be completed in 2024.

BAVARIAN NORDIC

Denmark-based Bavarian Nordic in April last year began a late-stage trial for its RSV vaccine in volunteers aged 60 years and older. Study results are expected by mid-2023. (Reporting by Raghav Mahobe and Nandhini Srinivasan in Bengaluru; Additional reporting by Mariam Sunny, Khushi Mandowara and Bhanvi Satija; Editing by Devika Syamnath, Sriraj Kalluvila, Shounak Dasgupta, Maju Samuel and Vinay Dwivedi)